2CHINESE ANTITUBERCULOSIS ASSOCIATION. Guidline for chem-otherapy of drug resistant TB (2015) [ J ].中国痨杂志,2015,37(5) :421-469.
3DEPARTmENT Of DISEASE CONTROL, mOH,DEPARTmENT OfmEDICAL ADmINISTRATION, mOH, CHINESE CENTER fORDISEASE CONTROL AND PREVENTION. Guidelines for Implemen-ting the National Tuberculosis Control Program in C/iina(2008)(中国结核病防冶规实施工作指南)[m]. Vol 2. Beijing:Pecking Unionmedical College Press, 2008,3.
4GUYATT G H, AKL E A, CROWTHER m, et al. Executivesummary : Antithrombotic Therapy and Prevention of Thrombosis,9lh ed: American College of Chest Physicians Evidence-BasedClinical Practice Guidelines [ J]. Chest,2012, 141 ( suppl 2 ):7S47S.
5JONAS D E,mCLEOD H L. Genetic and clinical factors relationto warfarin dosing [ J ]. Trends Pharmacol Sci,2009,30 ( 7 ):375-386.
6LAL S, JADA S H, XIANG X, et al. Pharmacogenetics of targetgens across the warfarin pharmacological pathway [ J ]. Clin Phar-macokinet, 2006,45(12) :1189-1200.
7mATAGRIN B, HODROGE A,mONTAG17T-ROmANS A, et al.New insights into the catalytic mechanism of vitamin K epoxide re-ductase (VKORCl)-The catalytic properties of the major mutationsof VKORC1 explain the biological cost associated to mutations[ J],fEBS Open Bio ,2013,3:144-150.
8GAIKWAD T, GHOSH K, KULKARNI B, et al Influence ofCYP2C9 and VKORC1 gene polymorphisms on warfarin dosage,over anticoagulation and other adverse outcomes in Indian popula-tion [J]. Eur J Pharmacol,2013 ,710( 1-3) :80-84.
9SHALIA K K, DOSHI S m, PARIKH S, et al. Prevalence ofVKORC1 and CYP2C9 gene polymorphisms in Indian populationand its effect on warfarin response[ J] . J 4s<soc Physicians India,2012,60:34-38.
10SHUEN A Y, WONG BY, fU L, et al. Evaluation of the warfa-rin-resistance polymorphism, VKORC1 Asp36Tyr, and its effecton dosage algorithms in a genetically heterogeneous anticoagulantclinic [J]. Clin SiocAem,2012,45(6) :397401.
